05:50 PM EDT, 07/01/2024 (MT Newswires) -- Codexis ( CDXS ) said Monday it agreed to sell its investigational Fabry and Pompe disease compounds to Crosswalk Therapeutics.

Codexis ( CDXS ) is eligible to receive development and commercial milestone payments along with a low-to-mid single-digit percentage net sales-based royalty.

The compounds were part of a collaboration agreement with Takeda Pharmaceuticals (TAK) that was discontinued in April 2023, Codexis ( CDXS ) said.